Send to

Choose Destination
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Collaborators (218)

Begbie S, Bonaventura A, Boyce A, Chua W, de Souza P, Davis I, Gardiner F, Guminski A, Gurney H, Hovey E, Mainwaring P, Marx G, Mathlum M, Parente P, Parnis F, Pook D, Rosenthal M, Shapiro J, Toner G, Warren M, Wong S, Woo H, Janetschek G, Krainer M, Loidl W, Schmeller N, Mebis J, Renard V, Tombal B, Van Poppel H, Waltregny D, Werbrouck P, Attwell A, Canil C, Drachenberg D, Finch D, Gleave M, Joshua AM, Klotz L, Lacombe L, Mukherjee S, Ruether D, Saad F, Venner P, Winquist E, Wood L, Borre M, Holm-Nielsen A, Iversen P, Langkilde NC, Ostri P, Rathenborg P, Taari K, Tammela T, Vaarala M, Ala-Opas M, Beuzeboc P, Bompas E, Davin JL, Delva R, Ducos B, Flechon A, Gross-Goupil M, Guillot A, Houédé N, Laguerre B, Latorzeff I, Lemoulec S, Loriot Y, Oudard S, Priou F, Vignot S, Voog E, Bögemann M, Bolenz C, Hadaschik B, Hammerer P, Klotz T, Merseburger A, Miller K, Ohlmann CH, Schrader M, Stenzl A, Strölin P, Suttmann H, Wirth M, Mermershtain W, Nativ O, Ramon J, Rosenbaum E, Sella A, Bracarda S, Cerbone L, De Giorgi U, Passalacqua R, Recine F, Scagliotti G, Sternberg C, Egawa S, Fukagai T, Fukumori T, Igawa T, Kamba T, Kimura G, Kosaka T, Matsuyama H, Nakatani T, Namiki S, Nishimura K, Nishiyama T, Nonomura N, Nozawa M, Numahata K, Okegawa T, Ueda T, Uemura H, Yamanaka Y, Yokomizo A, Yonese J, Jocys G, Ulys A, de Jong I, Mulders P, van den Eertwegh A, Vrijhof E, Dobrowolski A, Jassem J, Kalinka-Warzocha E, Kmieciak R, Milecki P, Al-Shukri S, Matveev V, Novikov A, Chiong E, Lau W, Balaz V, Brezovsky M, Goncalves F, Kliment J, Mincik I, Choi YD, Chung BH, Kim CS, Kwon DD, Lee HM, Lee KH, Lee SE, Alcaraz A, Bellmunt J, Burgos F, Carles J, Doménech M, Font A, Gallardo E, García-Donas Jiménez J, Gil-Bazo I, Gomez Veiga F, González A, Andrén O, Bjartell A, Damber JE, Ljungberg B, Wiklund P, Bahl A, Chowdhury S, de Bono J, Gilbert D, Hoskin P, Malik Z, McLaren D, Payne H, Pedley I, Protheroe A, Tanguay J, Waxman J, Andriole G, Appleman L, Armstrong A, Beer T, Berry W, Bolger G, Courtney K, Dorff T, Evans C, Flaig T, Fleming M, Haas N, Hall S, Hauke S, Higano C, Keane T, Khan M, Kohli M, Koletsky A, Kuzel T, McNeel D, Nazemzadeh R, Rathkopf D, Redfern C, Rettig M, Singh P, Srinivas S, Taplin ME, Vaishampayan U, Armstrong AJ, Beer TM, Higano CS, Iversen P, Sternberg CN, Tombal B, Andresen C, Martinez H, McNees A, Parli T, Pham T, Tabora K, Thomrongsith L, Zhao S.

Author information

The authors' affiliations are listed in the Appendix.



Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.


In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end points were radiographic progression-free survival and overall survival.


The study was stopped after a planned interim analysis, conducted when 540 deaths had been reported, showed a benefit of the active treatment. The rate of radiographic progression-free survival at 12 months was 65% among patients treated with enzalutamide, as compared with 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confidence interval [CI], 0.15 to 0.23; P<0.001). A total of 626 patients (72%) in the enzalutamide group, as compared with 532 patients (63%) in the placebo group, were alive at the data-cutoff date (29% reduction in the risk of death; hazard ratio, 0.71; 95% CI, 0.60 to 0.84; P<0.001). The benefit of enzalutamide was shown with respect to all secondary end points, including the time until the initiation of cytotoxic chemotherapy (hazard ratio, 0.35), the time until the first skeletal-related event (hazard ratio, 0.72), a complete or partial soft-tissue response (59% vs. 5%), the time until prostate-specific antigen (PSA) progression (hazard ratio, 0.17), and a rate of decline of at least 50% in PSA (78% vs. 3%) (P<0.001 for all comparisons). Fatigue and hypertension were the most common clinically relevant adverse events associated with enzalutamide treatment.


Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. (Funded by Medivation and Astellas Pharma; PREVAIL number, NCT01212991.).

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center